[Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Lansoprazole, a new substituted benzimidazole, is an effective acid proton pump inhibitor acting by inhibiting selectively H+/K+ ATPase of the gastric parietal cell. This study was performed to assess the effect of successive 30, 60, 90 and 120 mg dosages of lansoprazole in 4 patients suffering from Zollinger-Ellison syndrome. The basal gastric acid output was markedly inhibited in comparison with baseline values (mean maximal reduction: 87%; extremes: 75-99%) and was dose-related. Lansoprazole inhibited pepsin output globally with a dose range effect between 30 and 90 mg/day. The treatment induced a rapid relief of clinical symptoms. No biological abnormality was noted. These data proved that lansoprazole is efficient for treating gastric acid hypersecretion in patients suffering from ZES.
Mignon
M
M
Service d'Hépato-Gastroentérologie, CHU Bichat, Claude-Bernard, Université Paris VII.
Hochlaf
S
S
Forestier
S
S
Ruszniewski
P
P
Vatier
J
J
Joubert-Collin
M
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D005744:Gastric Acid / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole
Effet dose-réponse du lansoprazole chez des malades atteints d'un syndrome de Zollinger-Ellison.